Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescence Imaging and HRME in Endometrial Cancer
NCT02095847Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Primary completion
- Mar 2015
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
A Phase 2 trial of proflavine hemisulphate in endometrial cancer (EC), sponsored by University of Texas MD Anderson Cancer Center. Status: withdrawn.
02
Drugs
proflavine hemisulphate
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02095847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095847.